In animal studies, Nanobrite™ produces excellent renal vessel images, which should greatly improve the imaging of both normal renal vessels, as when kidney transplant donors are being evaluated, and abnormal vessels, as when renal artery stenosis or renal carcinoma patients are being evaluated. Furthermore, the significant population of patients with renal insufficiency who are currently excluded from evaluation using gadolinium based contrast agents (GBCAs) may be able to use Nanobrite™ with increased assurance of safety.

This Nanobrite™ technology has repeatedly demonstrated its advantages over commercially available contrast agents in animal models such as:

img3 Figure 1: Rat - 3T MRI dose comparisons in rats – all values are mmol/kg – arrows point to heart. In an imaging study in rats comparing commercially available Omniscan (A, 0.05 mmole/kg), Vasovist (B, 0.03 mmole/kg) against significantly lower doses of Nanobrite™ (C, 0.00125; D, 0.01 and E, 0.02 mmole/kg), superior images can be seen in images D and E versus A and B.

img3 Figure 2: Pig - Pig Renal Images. FP = First Pass. In studies using pigs, a comparison of the commercially available Ablavar revealed the images had greatly diminished from the First Pass of the contrast agent when reimaged at 15 minutes. In comparison, Nanobrite™ had a clear image of the vasculature at 20 minutes post injection.


In animal studies, Nanobrite™ has demonstrated superiority to current MRI contrast media by enhancing and improving the quality of magnetic resonance imaging [MRI] scans for diagnostic procedures.

In addition, the time required for the diagnostic procedure may be decreased without compromising the imaging quality.

If the animal data is reconfirmed in clinical trials, Nanobrite™ may carve out a larger slice of the current market, and more indications are being considered, such as utilizing MRI for cancer screening for e.g. breast and prostate cancer, while the medical specialist may initially look for indications where current contrast media was inadequate. And finally, hospital administrators may find the possibility for shortening the time of the diagnostic procedure without compromising the current imaging quality.

Superior images at lower doses than commercially available GBCAs